2 results
Approved WMOCompleted
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.
Approved WMOCompleted
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.